Misplaced Pages

SRT-2183: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 05:18, 5 October 2021 editCitation bot (talk | contribs)Bots5,445,378 edits Add: doi-access. | Use this bot. Report bugs. | Suggested by Headbomb | Linked from Misplaced Pages:WikiProject_Academic_Journals/Journals_cited_by_Wikipedia/Sandbox | #UCB_webform_linked 631/990← Previous edit Revision as of 23:13, 11 March 2022 edit undoLncallahan (talk | contribs)69 editsm added UNIINext edit →
Line 31: Line 31:
| ChEMBL = 403308 | ChEMBL = 403308
| PubChem = 24180126 | PubChem = 24180126
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6FKU9G9CX6
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = | DrugBank =

Revision as of 23:13, 11 March 2022

Pharmaceutical compound
SRT-2183
Clinical data
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • N-methyl}imidazothiazol-6-yl)phenyl]naphthalene-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H24N4O2S
Molar mass468.58 g·mol
3D model (JSmol)
SMILES
  • c1ccc2cc(ccc2c1)C(=O)Nc3ccccc3c4cn5c(csc5n4)CN6CC(C6)O
InChI
  • InChI=1S/C27H24N4O2S/c32-22-11-12-30(15-22)14-21-17-34-27-29-25(16-31(21)27)23-7-3-4-8-24(23)28-26(33)20-10-9-18-5-1-2-6-19(18)13-20/h1-10,13,16-17,22,32H,11-12,14-15H2,(H,28,33)/t22-/m1/s1
  • Key:MUFSINOSQBMSLE-JOCHJYFZSA-N
  (verify)

SRT-2183 is a drug in development by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. It has similar activity in animal studies to another SIRT1 activator SRT-1720, but is closer in potency to resveratrol. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. However, the claim that SRT-2183 is a SIRT1 activator has been questioned and further defended.

See also

References

  1. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. (November 2007). "Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes". Nature. 450 (7170): 712–6. Bibcode:2007Natur.450..712M. doi:10.1038/nature06261. PMC 2753457. PMID 18046409.
  2. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, et al. (March 2010). "SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1". The Journal of Biological Chemistry. 285 (11): 8340–51. doi:10.1074/jbc.M109.088682. PMC 2832984. PMID 20061378.
  3. Dai H, Kustigian L, Carney D, Case A, Considine T, Hubbard BP, et al. (October 2010). "SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator". The Journal of Biological Chemistry. 285 (43): 32695–703. doi:10.1074/jbc.M110.133892. PMC 2963390. PMID 20702418.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: